Your browser doesn't support javascript.
loading
International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease.
Laansma, Max A; Bright, Joanna K; Al-Bachari, Sarah; Anderson, Tim J; Ard, Tyler; Assogna, Francesca; Baquero, Katherine A; Berendse, Henk W; Blair, Jamie; Cendes, Fernando; Dalrymple-Alford, John C; de Bie, Rob M A; Debove, Ines; Dirkx, Michiel F; Druzgal, Jason; Emsley, Hedley C A; Garraux, Gäetan; Guimarães, Rachel P; Gutman, Boris A; Helmich, Rick C; Klein, Johannes C; Mackay, Clare E; McMillan, Corey T; Melzer, Tracy R; Parkes, Laura M; Piras, Fabrizio; Pitcher, Toni L; Poston, Kathleen L; Rango, Mario; Ribeiro, Letícia F; Rocha, Cristiane S; Rummel, Christian; Santos, Lucas S R; Schmidt, Reinhold; Schwingenschuh, Petra; Spalletta, Gianfranco; Squarcina, Letizia; van den Heuvel, Odile A; Vriend, Chris; Wang, Jiun-Jie; Weintraub, Daniel; Wiest, Roland; Yasuda, Clarissa L; Jahanshad, Neda; Thompson, Paul M; van der Werf, Ysbrand D.
Afiliação
  • Laansma MA; Department of Anatomy & Neurosciences, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Bright JK; Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, California, USA.
  • Al-Bachari S; Faculty of Health and Medicine, The University of Lancaster, Lancaster, UK.
  • Anderson TJ; Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Ard T; Department of Neurology, Royal Preston Hospital, Preston, UK.
  • Assogna F; Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand.
  • Baquero KA; Department of Neurology, USC Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, California, USA.
  • Berendse HW; Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.
  • Blair J; GIGA-CRC In Vivo Imaging, University of Liège, Liège, Belgium.
  • Cendes F; Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Dalrymple-Alford JC; Department of Medical Imaging, University of Virginia Health System, Charlottesville, Virginia, USA.
  • de Bie RMA; Neuroimaging Laboratory, Department of Neurology, University of Campinas, Campinas, Brazil.
  • Debove I; New Zealand Brain Research Institute, Christchurch, New Zealand.
  • Dirkx MF; School of Psychology, Speech and Hearing, University of Canterbury, Christchurch, New Zealand.
  • Druzgal J; Brain Research New Zealand - Rangahau Roro Aotearoa, Centre of Research Excellence, Auckland, New Zealand.
  • Emsley HCA; Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Garraux G; Department of Neurology, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland.
  • Guimarães RP; Department of Neurology and Center of Expertise for Parkinson & Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
  • Gutman BA; Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Nijmegen, the Netherlands.
  • Helmich RC; Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia, USA.
  • Klein JC; Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Mackay CE; Lancaster Medical School, Lancaster University, Preston, UK.
  • McMillan CT; GIGA-CRC In Vivo Imaging, University of Liège, Liège, Belgium.
  • Melzer TR; Department of Neurology, CHU Liège, Liège, Belgium.
  • Parkes LM; Neuroimaging Laboratory, Department of Neurology, University of Campinas, Campinas, Brazil.
  • Piras F; Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, USA.
  • Pitcher TL; Department of Neurology and Center of Expertise for Parkinson & Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
  • Poston KL; Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Nijmegen, the Netherlands.
  • Rango M; Department of Clinical Neurosciences, Division of Clinical Neurology, Oxford Parkinson's Disease Centre, Nuffield, University of Oxford, Oxford, UK.
  • Ribeiro LF; Department of Psychiatry, University of Oxford, Oxford, UK.
  • Rocha CS; University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Rummel C; Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand.
  • Santos LSR; New Zealand Brain Research Institute, Christchurch, New Zealand.
  • Schmidt R; Brain Research New Zealand - Rangahau Roro Aotearoa, Centre of Research Excellence, Auckland, New Zealand.
  • Schwingenschuh P; Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Spalletta G; Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.
  • Squarcina L; Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand.
  • van den Heuvel OA; New Zealand Brain Research Institute, Christchurch, New Zealand.
  • Vriend C; Brain Research New Zealand - Rangahau Roro Aotearoa, Centre of Research Excellence, Auckland, New Zealand.
  • Wang JJ; Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, California, USA.
  • Weintraub D; Excellence Center for Advanced MR Techniques and Parkinson's Disease Center, Neurology Unit, Fondazione IRCCS Cà Granda Maggiore Policlinico Hospital, University of Milan, Milan, Italy.
  • Wiest R; Neuroimaging Laboratory, Department of Neurology, University of Campinas, Campinas, Brazil.
  • Yasuda CL; Neuroimaging Laboratory, Department of Neurology, University of Campinas, Campinas, Brazil.
  • Jahanshad N; Department of Medical Genetics, University of Campinas, Campinas, Brazil.
  • Thompson PM; Support Center for Advanced Neuroimaging (SCAN), University Institute of Diagnostic and Interventional Neuroradiology, University Hospital Bern, Bern, Switzerland.
  • van der Werf YD; Neuroimaging Laboratory, Department of Neurology, University of Campinas, Campinas, Brazil.
Mov Disord ; 36(11): 2583-2594, 2021 11.
Article em En | MEDLINE | ID: mdl-34288137
ABSTRACT

BACKGROUND:

Brain structure abnormalities throughout the course of Parkinson's disease have yet to be fully elucidated.

OBJECTIVE:

Using a multicenter approach and harmonized analysis methods, we aimed to shed light on Parkinson's disease stage-specific profiles of pathology, as suggested by in vivo neuroimaging.

METHODS:

Individual brain MRI and clinical data from 2357 Parkinson's disease patients and 1182 healthy controls were collected from 19 sources. We analyzed regional cortical thickness, cortical surface area, and subcortical volume using mixed-effects models. Patients grouped according to Hoehn and Yahr stage were compared with age- and sex-matched controls. Within the patient sample, we investigated associations with Montreal Cognitive Assessment score.

RESULTS:

Overall, patients showed a thinner cortex in 38 of 68 regions compared with controls (dmax  = -0.20, dmin  = -0.09). The bilateral putamen (dleft  = -0.14, dright  = -0.14) and left amygdala (d = -0.13) were smaller in patients, whereas the left thalamus was larger (d = 0.13). Analysis of staging demonstrated an initial presentation of thinner occipital, parietal, and temporal cortices, extending toward rostrally located cortical regions with increased disease severity. From stage 2 and onward, the bilateral putamen and amygdala were consistently smaller with larger differences denoting each increment. Poorer cognition was associated with widespread cortical thinning and lower volumes of core limbic structures.

CONCLUSIONS:

Our findings offer robust and novel imaging signatures that are generally incremental across but in certain regions specific to disease stages. Our findings highlight the importance of adequately powered multicenter collaborations. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson Idioma: En Ano de publicação: 2021 Tipo de documento: Article